Aims: In 1970, Breslow described his eponymously named thickness measurement. No-one has sought to enhance the Breslow thickness (BT). The aim of this study was to demonstrate a proof of concept that the density of melanoma cells at the position where the BT is measured is a morphological prognostic biomarker, which we name the Breslow density (BD). The hypothesis was that the BD has prognostic value for overall survival (OS) and is independent of the BT. Methods and results: We analysed 100 cutaneous melanomas, and followed REMARK guidelines. The BD was the estimated percentage dermal area occupied by melanoma cells in a specified location. The BT and BD had a strong correlation (P = 2.1 9 10 À11 ) but, despite this, they were independent prognostic factors for OS in Cox regression [BD hazard ratio (HR) 1.03, P = 0.001849; and BT HR 1.09, P = 0.000146]. This was corroborated by an independent effect on melanoma-specific survival. We assessed whether the BT and BD could be combined into a Breslow score. A prognostic index based on Cox regression coefficients was used, and this showed a marginal improvement in predicted 5-year survival as compared with the BT alone (area under the curve of 94.8% versus 96.7%). Conclusions: We show a proof of concept that the BD represents a novel morphological prognostic biomarker that is independent of the BT, and that there is potential to combine these into a Breslow score. Larger studies are needed to validate the BD, but the simplicity of this biomarker makes it a strong candidate for translation to clinical practice.
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Conclusions:
We show a proof of concept that the BD represents a novel morphological prognostic biomar
Introduction
In 1970, Breslow described a measurement for melanoma invasion, now known as the Breslow thickness (BT), 1 and demonstrated that this correlated with the risk of metastasis. In particular, he found that no melanoma with a thickness of <0.76 mm developed into further disease. Although this study was small, comprising only 98 patients, the broad findings have been reproduced many times during the subsequent decades, with the result that the BT is now regarded as a robust evidence-based data item and has been the foundation for the T-stage parameter in successive versions of the American Joint Committee on Cancer (AJCC) TNM staging system. 2 Several other morphological features in the primary melanoma have shown prognostic value, with varying degrees of support from the literature. Ulcer and mitotic rate are established prognostic factors that are recognized for their central role in AJCC staging. 2 Clark level is also important, but it has been superseded as a major determinant in AJCC staging by mitotic rate. The prognostic value of other morphological features, such as tumour-infiltrating lymphocytes [3] [4] [5] [6] and regression, [7] [8] [9] [10] [11] [12] is controversial, owing to conflicting reports in the literature.
In his original article, Breslow was seeking a simple surrogate for tumour volume, 1 which seems reasonable if one assumes that the total dermal invasive burden would be the feature with strongest prognostic impact. One can envisage a sequence of increasing complexity for estimating invasive burden, ranging from the BT at the simplest, to measuring the density of cells at the position where the BT is measured, to measuring the cross-sectional area of invasive cells in the whole section where the BT is measured, and finally to measuring the total invasive volume across all sections. However, the difficulty of achieving these measurements in day-to-day practice increases as we move across this spectrum from the BT to total invasive volume. For example, the latter would require the whole melanoma to be embedded in every case, assessment of the tumour cross-sectional area in each slice, and knowledge of the thickness of each slice to compute total tumour volume. This would be timeconsuming to perform. One reason why the BT is powerful is that it so simple to measure and is reproducible. Surprisingly, the easiest of the aforementioned BT enhancements for estimating invasive burden, namely measuring the density of melanoma cells at the position where the BT is measured, has never been assessed. It seems reasonable that, of two melanomas with the same BT but differing densities of cells at the position of measurement, the one with fewer invasive cells will have a better prognosis. Thus, we propose a new measurement, the 'Breslow density' (BD), to capture this hitherto unmeasured variable. This aim of this study was to describe a method to measure the BD by making an estimate of the melanoma cell area in a specified location, to demonstrate a proof of concept that this would be a viable, simple and reproducible morphological prognostic biomarker, and to determine whether detailed future evaluation is warranted. The primary hypothesis was that the BD has prognostic value for overall survival (OS) and that it is independent of the BT. A secondary aim was to analyse melanoma-specific survival (MSS). Finally, we aimed to show a proof of concept that the BD might be used in combination with the BT to yield a Breslow score (BS).
Materials and methods

P A T I E N T S
Tissues were selected from the archives of the University Hospitals of Leicester Cellular Pathology department. A favourable opinion from a National Health Service ethics committee was obtained for tissue use.
A search of melanoma cases from 1 January 2004 was performed, and patients with cutaneous melanoma, showing invasive disease and diagnosed in Leicestershire were sequentially selected until a total of 100 was reached. Selection was stopped at this point because there were sufficient events for the primary analysis of OS (35 deaths) to analyse two covariates, the BD and BT, alongside an interaction term, with the rule of thumb that~10 events per covariate are required. We excluded five patients: slide stain too faded (n = 1), slides not in file (n = 2), and metastasis at diagnosis (n = 2). Patients living outside Leicestershire were not included in the target population, because follow-up could not be accurately ascertained for patients receiving care in other regions. Clinical stage was defined according to AJCC version 7.
B R E S L O W D E N S I T Y
The BD was measured at the invasive area where the BT was measured with the same formalin-fixed paraffin-embedded sections as used by the reporting histopathologist. The BD was measured according to a protocol as described below and graphically summarized in Figure 1A . First, the location containing the deepest cells, and hence the position where the BT had been measured, was identified. Second, on the assumption that the axis perpendicular to the epidermis is vertical and that the axis parallel is horizontal, a rectangular virtual window was created at low power. In the horizontal axis, the window was limited by the crudely estimated width of a 910 field (2.1 mm with an Olympus BX45 microscope (Olympus, Southend-on-Sea, UK) equipped with a Plan 910/0.25 objective), this estimate being achieved by switching between 910 and lower-power objectives as required. In the vertical axis, this was limited superiorly by the epidermal basal layer and inferiorly by the deepest melanoma cell. The window was positioned such that a vertical line bisecting it passed through the deepest melanoma cell. Third, at low power, the estimated window was adjusted in the horizontal axis such that it maximized the dermal area occupied by melanoma cells while still containing the deepest melanoma cell. Fourth, the field of view was centred on the estimated window from the previous step, and the view was switched from low power to the 910 objective. Histological landmarks that defined the two horizontal edges of the 910 field (e.g. a specific rete tip, hair follicle, tumour/inflammatory cell cluster, or sweat duct) were identified, and the field was switched back to low power. A precise rectangular window was mentally reconstructed from the horizontal landmarks, the basal layer of the epidermis, and the deepest cell. In this way, the full window could be assessed at scanning power. We found in practice that being able visualize the whole rectangle at once made scoring much easier. However, with very thick melanomas, the field was not seen even at low power, so vertical scanning was required to see the whole rectangular area. Horizontal landmarks were easy to find in every case. The percentage area of dermal stromal tissue occupied by melanoma cells was recorded as the BD to the nearest 5%, but with precision to the nearest 1% for scores of <5% and >95%. It thus follows from the above protocol that the window was always created at a fixed location (a position that contained the deepest melanoma cell), its horizontal dimension was always the same for every case (the width of the 910 field; 2.1 mm for our microscope), and its vertical dimension varied from case to case, being the same as the BT. Importantly, however, all tumours with the same BT had the same window area, allowing for meaningful evaluation of the BD relative to the BT, as shown in Figure 1C ,D. It is important to note that, although the method seems cumbersome to describe, it was very easy to execute once the position of BT measurement was identified, typically taking less than a minute and often only a matter of seconds.
S T A T I S T I C A L A N A L Y S E S
Statistical analyses were all performed in R version 3.2.0. 13 Survival analysis was performed with the 'survival' package.
14 The BT, measured in millimetres, and the BD, measured as a percentage, were analysed as continuous variables. For correlation, Pearson's correlation coefficient was used. Time-toevent analysis was performed with two outcomes: MSS and OS. For both, the date of diagnosis was taken as the date of primary sample accession in the pathology laboratory. For MSS, death from melanoma was considered to be failure, and for OS, death from any cause was considered to be failure. For MSS, death from another cause was regarded as censoring. Survival was analysed with the Kaplan-Meier method, with the BD and BT split at the median to create two groups, and the log rank test was used to compare survival curves. For Kaplan-Meier analysis of MSS, there were 55 cases in the low BD score group with four events, and 45 in the high BD score 
Results
The study evaluated 100 melanomas, which were all cutaneous. The baseline features of the cases included in the study are shown in Table 2 . The variable of interest in the present study, the BD, was checked for interobserver agreement by two histopathologists, who performed independent scoring of a random sample of 20 cases. This showed an intraclass correlation coefficient of 0.96, indicating almost perfect agreement. Aspects of BD scoring are shown in Figure 1 .
B D S C O R E C O R R E L A T E S W I T H B T
Our primary aim was to determine whether BD has an independent effect on survival, but, as a preliminary investigation, we sought to determine whether it showed evidence of correlation with BT, because, if present, this would indicate the importance of multivariable survival analysis to rule out confounding. The two variables are plotted in Figure 2 . A scatterplot of the BD against log BT was created. A log transformation of the BT was performed because outlying BT values were high. The BD and BT had a strong correlation (Pearson R 2 = 0.61, t = 7.57, degrees of freedom = 98, P = 2.1 9 10 À11 ). This indicated that there was a high possibility that any effect of the BD on survival could be confounded by the BT.
B D H A S A N E F F E C T O N M S S
In order to determine the possible effect of the BD on survival, we first performed univariable analysis with Kaplan-Meier estimates of the survivor function. The BT and BD were assessed with MSS and OS as timeto-event outcomes. The BD and BT were both split at Table 2 Analyses Bivariate 100 BD versus natural log BT the median into two approximately equal-sized groups, and the survivor curves were compared by use of the log rank test. The data are shown in Figure 3 . In order to determine whether the BD is confounded by the BT, and also to assess for any interaction between these variables, a Cox proportional hazards regression model was used. Univariable models for the BD and BT were fitted, and then multivariable models with and without an interaction term. These are summarized in Table 3 . They reveal that the BD is independent of the BT in determining both MSS and OS. The analysis also shows that there is a significant negative interaction for MSS and an interaction just short of significant for OS, implying that the effect of the BD on survival is reduced at higher BT values.
T H E C O M B I N A T I O N O F B D A N D B T S H O W S A M A R G I N A L I M P R O V E M E N T I N P R E D I C T I N G 5 -Y E A R S U R V I V A L
In order to determine whether the BD and BT could be used to create a BS, they were combined. This was achieved by taking a linear combination of the BD and BT weighted by the coefficient values from the Cox proportional hazards model to yield a prognostic index (PI). The PI thus represented the log of the HR. For each of MSS and OS, a PI was calculated for two different regression models, one containing the BD and BT, and one containing the BD, BT and BD 9 BT interaction term, given that this was significant for MSS and nearly significant for OS. The BD, BT and PIs from the multivariable regression models were used to assess the ability to discriminate between patients surviving for up to and including 5 years and those surviving beyond 5 years, with MSS and OS as endpoints. The receiver operating characteristic (ROC) curves are shown in Figure 4 . The combination of the BD and BT showed improvement in areas under ROC curves, albeit marginal, indicating the potential for the BT and BD to be combined into an overall BS to more accurately classify melanoma outcome. The addition of the interaction term to the regression model was not of value.
Discussion
To our knowledge, no-one has ever sought to enhance the BT by determining the density of malignant melanoma cells at the point of BT measurement. Our data show that, although the BT and BD have a strong correlation, they remain independent prognostic factors, and furthermore have the potential to be combined into a single variable, the BS, to discriminate 5-year survival with greater accuracy. The present study shows that the combination of the BT and BD shows only a marginal improvement over the BT alone, and further studies are needed to determine the optimal way in which the BD might be used in practice. Breslow, in his original article, sought a measurement of invasive volume, but found that thickness was the best predictor. 1 Invasive volume has not been widely studied in cutaneous melanoma. Friedman conducted a small study on 35 melanomas, and showed that 200 mm 3 was a cut-off for good and poor 5-year survival. 16 A method for estimating tumour volume from macroscopic specimens by using slices of known thickness with the Cavalieri method showed good correlation with the BT, but the prognostic value of this estimation was not then assessed. 17 More recently, tumour volume was found to be a prognostic factor in 122 melanomas, including cases for which low thickness but high volumes correlated with poorer outcome. 18 We speculate that the invasive burden of melanoma cells represented by the total invasive cell count is the best predictor of outcome, and that total invasive volume is likely to be the best approximation of this. However, its clinical value is limited by the relative difficulty of measurement, such that histopathologists may be unwilling to adopt this into routine practice. In contrast, the BD is undoubtedly a poorer estimate of invasive burden, but represents the simplest next best step up from the BT, and would be very easy for pathologists to perform. This study is limited by its small size, but the case number was purposely chosen in order to have sufficient power to make an initial proof-of-concept estimate of the value of the BD for future study, with the primary outcome of OS. As such, the study size was powered to allow the inclusion of the BT, the BD, and an interaction term, which, for preliminary investigation, represent the most crucial prognostic predictors, in a multivariable analysis of OS. Future studies will need higher case numbers so that the BD can be evaluated against other recognized clinicopathological features for better evaluation of confounding features and to have greater power to develop a combined BT/BD score. In turn, a BS would need to be externally validated in the future for it to be generalized for use. The BD is a semiquantitative scoring system, and as such is subject to all of the pitfalls associated with this type of measurement, most notably the inherent element of subjectivity in estimating a percentage score. However, the very high intraclass correlation suggests that subjectivity was not a major issue for the authors. If difficulty did arise, it was for cases with expansile junctional nests (specifically, deciding which cells were invasive) and cases with heavy inflammation (deciding which cells were melanoma), but these issues were not especially taxing for our cases. A more pressing methodological concern was how precise the scoring should be, and in particular whether a score to the nearest 5% (nearest 1% at extreme values) was overly exact. Given that this was just a proof-of-concept study, the optimal precision for BD scoring will need to be defined as we move forwards. The likelihood is that pathologists in different centres will achieve poorer scoring agreement than colleagues in the same centre, and so a less precise scoring system may be better in the future.
The strength of this study lies in the fact that the primary analysis of OS was corroborated by a secondary analysis of MSS. Other strengths are that the BD is very simple to measure, and we find that, once the position for measuring BT is established, it takes only a matter of seconds to make an estimate of the density of melanoma cells, and that the BD percentage was reproducible between two raters. It is likely that melanoma cell immunostains with or without image analysis would improve BD scoring accuracy. However, the benefit would be offset by the increase in time, cost, and (in the case of image analysis) the availability of relevant software and hardware directly at the microscope. The value of image analysis is something that would require a specific study to evaluate in the future, whereas we can see clear immediate benefits for immunostains in cases where melanoma cells are difficult to see, e.g. cases with very brisk lymphocytic infiltrates.
In conclusion, we have identified a novel enhancement to the BT for estimating prognosis, and show that the BT and BD have the potential to be employed in combination. We are currently seeing remarkable improvements in the understanding of melanoma molecular pathology, with a resultant flood of potential molecular prognostic biomarkers. Such biomarkers are crucial, because obtaining the most accurate prognosis at baseline is fundamental to all further melanoma patient care. However, it is very easy to forget that a simple morphological biomarker has advantages over a molecular biomarker, because any complex analytical procedures are eliminated and can be replaced with a simple morphological measurement performed prospectively at the microscope by a pathologist as part of routine reporting. In turn, this makes it simpler to incorporate a morphological biomarker into daily practice for translation. The BD fulfils these criteria for being a simple morphological biomarker, and should be prioritized for further development.
